Mi-Young Kim

Mi-Young Kim

Auto-generated profile, based on publicly available information

Mi-Young Kim

Department of Biological Sciences Korea Advanced Institute of Science and Technology (KAIST) Daejeon Republic of Korea

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
JLJae Eun Lee
Jae Eun Lee
MKMi-Young Kim
Mi-Young Kim

16 December 2016 in Nature Communications
Verified
Journal Article
Open access
KSKi-Hoon Song
Ki-Hoon Song
MPMi So Park
Mi So Park
TNTulip Nandu
Tulip Nandu
SGShrikanth Gadad
Shrikanth Gadad
SKSang-Cheol Kim
Sang-Cheol Kim
MKMi-Young Kim
Mi-Young Kim
Some polypeptide N-acetyl-galactosaminyltransferases (GALNTs) are associated with cancer, but their function in organ-specific metastasis remains unclear. Here, we report that GALNT14 promotes breast cancer metastasis to the lung by enhancing the initiation of metastatic colonies as well as their subsequent growth into overt metastases. Our results suggest that GALNT14 augments the self-renewal properties of breast cancer cells (BCCs). Furthermore, GALNT14 overcomes the inhibitory effect of lung-derived bone morphogenetic proteins (BMPs) on self-renewal and therefore facilitates metastasis initiation within the lung microenvironment. In addition, GALNT14 supports continuous growth of BCCs in the lung by not only inducing macrophage infiltration but also exploiting macrophage-derived fibroblast growth factors (FGFs). Finally, we identify KRAS-PI3K-c-JUN signalling as an upstream pathway that accounts for the elevated expression of GALNT14 in lung-metastatic BCCs. Collectively, our findings uncover an unprecedented role for GALNT14 in the pulmonary metastasis of breast cancer and elucidate the underlying molecular mechanisms.

14 May 2021
Verified
Book Chapter
Closed access
PDF file
MKMi Young Kim
Mi Young Kim

1 January 2016 in Cancer Research
Verified
Journal Article
Closed access
PDF file
WPWoo-Yong Park
Woo-Yong Park
BHBeom-Jin Hong
Beom-Jin Hong
JLJungsul Lee
Jungsul Lee
CCChulhee Choi
Chulhee Choi
MKMi-Young Kim
Mi-Young Kim
Histone methylation is a key epigenetic mark that regulates gene expression. Recently, aberrant histone methylation patterns caused by deregulated histone demethylases have been associated with carcinogenesis. However, the role of histone demethylases, particularly the histone H3 lysine 27 (H3K27) demethylase JMJD3, remains largely uncharacterized in melanoma. Here, we used human melanoma cell lines and a mouse xenograft model to demonstrate a requirement for JMJD3 in melanoma growth and metastasis. Notably, in contrast with previous reports examining T-cell acute lymphoblastic leukemia and hepatoma cells, JMJD3 did not alter the general proliferation rate of melanoma cells in vitro. However, JMJD3 conferred melanoma cells with several malignant features such as enhanced clonogenicity, self-renewal, and transendothelial migration. In addition, JMJD3 enabled melanoma cells not only to create a favorable tumor microenvironment by promoting angiogenesis and macrophage recruitment, but also to activate protumorigenic PI3K signaling upon interaction with stromal components. Mechanistic investigations demonstrated that JMJD3 transcriptionally upregulated several targets of NF-κB and BMP signaling, including stanniocalcin 1 (STC1) and chemokine (C–C motif) ligand 2 (CCL2), which functioned as downstream effectors of JMJD3 in self-renewal and macrophage recruitment, respectively. Furthermore, JMJD3 expression was elevated and positively correlated with that of STC1 and CCL2 in human malignant melanoma. Moreover, we found that BMP4, another JMJD3 target gene, regulated JMJD3 expression via a positive feedback mechanism. Our findings reveal a novel epigenetic mechanism by which JMJD3 promotes melanoma progression and metastasis, and suggest JMJD3 as a potential target for melanoma treatment. Cancer Res; 76(1); 161–70. ©2016 AACR.

1 February 2019 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
HLHo Yeon Lee
Ho Yeon Lee
JCJunghwa Cha
Junghwa Cha
SKSeon Kyu Kim
Seon Kyu Kim
JPJun Hyung Park
Jun Hyung Park
KSKi Hoon Song
Ki Hoon Song
MKMi-Young Kim
Mi-Young Kim
Brain metastasis in breast cancer is particularly deadly, but effective treatments remain out of reach due to insufficient information about the mechanisms underlying brain metastasis and the potential vulnerabilities of brain-metastatic breast cancer cells. Here, human breast cancer cells and their brain-metastatic derivatives (BrMs) were used to investigate synthetic lethal interactions in BrMs. First, it was demonstrated that c-MYC activity is increased in BrMs and is required for their brain-metastatic ability in a mouse xenograft model. Specifically, c-MYC enhanced brain metastasis by facilitating the following processes within the brain microenvironment: (i) invasive growth of BrMs, (ii) macrophage infiltration, and (iii) GAP junction formation between BrMs and astrocytes by upregulating connexin 43 (GJA1/Cx43). Furthermore, RNA-sequencing (RNA-seq) analysis uncovered a set of c-MYC–regulated genes whose expression is associated with higher risk for brain metastasis in breast cancer patients. Paradoxically, however, increased c-MYC activity in BrMs rendered them more susceptible to TRAIL (TNF-related apoptosis-inducing ligand)–induced apoptosis. In summary, these data not only reveal the brain metastasis-promoting role of c-MYC and a subsequent synthetic lethality with TRAIL, but also delineate the underlying mechanism. This suggests TRAIL-based approaches as potential therapeutic options for brain-metastatic breast cancer. Implications: This study discovers a paradoxical role of c-MYC in promoting metastasis to the brain and in rendering brain-metastatic cells more susceptible to TRAIL, which suggests the existence of an Achilles' heel, thus providing a new therapeutic opportunity for breast cancer patients.

1 November 2021 in Cancer Letters
Verified
Journal Article
Closed access
MPMi So Park
Mi So Park
AYA-Yeong Yang
A-Yeong Yang
JLJae Eun Lee
Jae Eun Lee
SKSeon Kyu Kim
Seon Kyu Kim
JRJae-Seok Roe
Jae-Seok Roe
MKMi-Young Kim
Mi-Young Kim